The licensing of the DOAC may vary according to the local authorities.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
In the field of thrombosis and hemostasis the focus was laid on the prophylaxis and treatment of venous thromboembolism in patients with active cancer during this years’ meeting of the American Society of Hematology (ASH) in San Diego. The Adam-VTE trial completed the series of studies using Xa-antagonists for the treatment of cancer-associated thromboembolism. Apixaban reduced the number of recurrent thromboembolic events compared to treatment with dalteparin without increasing the bleeding risk. Furthermore, the use of a prophylactic dose of rivaroxaban or apixaban showed positive results in the primary prevention of venous thromboembolism in ambulatory cancer patients being at high risk for thromboembolic events. A safe standardized perioperative management for direct oral anticoagulants was also presented during the meeting in noncancer patients with atrial fibrillation. This short review will summarize the most clinically relevant highlights in the field of thrombosis and hemostasis of the ASH meeting 2018.
Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–46. CrossRef
Douketis J, Spyropoulos AC, Duncan JM, et al. Perioperative anticoagulant use for surgery evaluation (PAUSE) study: a Perioperative management plan for patients with atrial fibrillation who are receiving a direct oral anticoagulant. Blood. 2018;132:LBA-5. https://doi.org/10.1182/blood-2018-120770. CrossRef
Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53. CrossRef
Young AM, Marshall A, Thirlwall J, Chapman O, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous Thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23. https://doi.org/10.1200/JCO.2018.78.8034. CrossRef
Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452–e66. https://doi.org/10.1016/S1470-2045(16)30369-2. CrossRefPubMed
Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thromb Res. 2017;151:89–95. https://doi.org/10.1016/j.thromres.2017.01.009. CrossRefPubMed
Di Nisio M, Porreca E, Candeloro M, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12:CD8500. https://doi.org/10.1002/14651858.CD008500.pub4. CrossRefPubMed
- Update in thrombosis and hemostasis: ASH meeting 2018
MD Clemens Feistritzer
- Springer Vienna
memo - Magazine of European Medical Oncology
An International Journal for Oncology and Haematology Professionals
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
Neu im Fachgebiet Onkologie
Mail Icon II